P571: Frequency and risk factors of advanced neoplasia in Korean IBD patients with Low Grade Dysplasia in previous surveillanceECCO’23 CopenhagenYear: 2023
Authors: Park, Y.E.(1)*;Kim, D.H.(2);Park, S.K.(3);Lee, Y.J.(4);Lee, C.K.(5);Kim, E.S.(6);Kim, K.O.(7);
(1)Inje University School of Medicine- Haeundae Paik Hospital, Division of Gastroenterology- Department of Internal Medicine, Busan, Korea- Republic Of;(2)Chonnam National University Hospital- Chonnam National University Medical School, Division of Gastroenterology- Department of Internal Medicine, Gwangju, Korea- Republic Of;(3)Kangbuk Samsung Hospital- Sungkyunkwan University School of Medicine, Division of Gastroenterology- Department of Internal Medicine and Gastrointestinal Cancer Center, Seoul, Korea- Republic Of;(4)Dongsan Medical Center- Keimyung University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Daegu, Korea- Republic Of;(5)Kyung Hee University-, Department of Internal Medicine- School of Medicine, Seoul, Korea- Republic Of;(6)Kyungpook National University, Division of Gastroenterology- Department of Internal Medicine- School of Medicine, Daegu, Korea- Republic Of;(7)Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Daegu, Korea- Republic Of;
P572: Coexisting Inflammatory bowel disease and Ankylosing spondylitis: Management and clinical outcomesECCO’23 CopenhagenYear: 2023
Authors: Savin, E.(1)*;Levartovsky, A.(2);Gendelman, O.(3);Lidar, M.(3);Ben-Horin, S.(2);Kopylov, U.(2);
(1)Sheba Medical Center, Department of Medicine 'B', Tel-Hashomer- Ramat Gan, Israel;(2)Sheba Medical Center, Department of Gastroenterology, Tel-Hashomer- Ramat Gan, Israel;(3)Sheba Medical Center, Rheumatology Unit, Tel-Hashomer- Ramat Gan, Israel;
P573: Change in fatigue in patients with Ulcerative Colitis or Crohn's disease initiating vedolizumab or other biologic therapy: Data from Belgian registry patientsECCO’23 CopenhagenYear: 2023
Authors: Louis, E.(1)*;Bossuyt, P.(2);Colard, A.(3);Caenepeel, P.(4);Baert, F.(5);Hantson, A.(6);Van Gassen, G.(6);Zhou, J.(7);Vermeire, S.(8);
(1)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;(2)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(3)Hospital CHC, Department of Gastroenterology, Liège, Belgium;(4)Ziekenhuis Oost Limburg, Department of Gastroenterology, Genk, Belgium;(5)AZ Delta, Department of Gastroenterology, Roeselare, Belgium;(6)Takeda, Gastroenterology, Brussels, Belgium;(7)Takeda, Gastroenterology, Cambridge- MA, United States;(8)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;
P574: Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Siegmund, B.(1)*;Ryan, R.(2);Abreu, M.T.(3);Vermeire, S.(4);Dotan, I.(5,6);Goetsch, M.(7);Crosby, C.(8);Woolcott, J.(9);Komori, H.K.(10);Danese, S.(11);
(1)Charité - Universitätsmedizin Berlin, Medizinische Klinik für Gastroenterologie, Berlin, Germany;(2)Pfizer Inc, Biomarker Statistics, New York- New York, United States;(3)University of Miami Miller School of Medicine, Gastroenterology, Miami- Florida, United States;(4)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(5)Division of Gastroenterology- Rabin Medical Center, Gastroenterology, Petah Tikva, Israel;(6)Sackler Faculty of Medicine- Tel Aviv University, Gastroenterology, Tel Aviv, Israel;(7)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(8)Pfizer Inc, Translational Medicine, New York- New York, United States;(9)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(10)Kinevant Sciences, Translational Research, San Diego- California, United States;(11)Gastroenterology and Endoscopy- IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;
P575: Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Siegmund, B.(1)*;Komori, H.K.(2);Abreu, M.T.(3);Vermeire, S.(4);Dotan, I.(5,6);Goetsch, M.(7);Crosby, C.(8);Ryan, R.(9);Woolcott, J.(10);Danese, S.(11);
(1)Medizinische Klinik für Gastroenterologie- Infektiologie und Rheumatologie- Charité - Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany;(2)Kinevant Sciences, Translational Research, San Diego- California, United States;(3)University of Miami Miller School of Medicine, Gastroenterology, Miami- Florida, United States;(4)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(5)Division of Gastroenterology- Rabin Medical Center, Gastroenterology, Petah Tikva, Israel;(6)Sackler Faculty of Medicine- Tel Aviv University, Gastroenterology, Tel Aviv, Israel;(7)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(8)Pfizer Inc, Translational Medicine, New York- New York, United States;(9)Pfizer Inc, Biomarker Statistics, New York- New York, United States;(10)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(11)Gastroenterology and Endoscopy- IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;
P576: Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CDECCO’23 CopenhagenYear: 2023
Authors: D'Haens, G.(1)*;Bossuyt, P.(2);Baert, F.(3);Molnár, T.(4);Clasquin, E.(1);Lowenberg, M.(1);Montazeri, N.(1);Peeters, H.(5);Lambrecht, G.(6);Vermeire, S.(7);
(1)Amsterdam University Medical Centres, Gastroenterology, Amsterdam, The Netherlands;(2)Imelda General Hospital, Gastroenterology, Bonheiden, Belgium;(3)AZ Delta, Gastroenterology, Roeselare, Belgium;(4)University of Szeged, Internal Medicine, Szeged, Hungary;(5)St Lukas Hospital, Gastroenterology, Gent, Belgium;(6)MSD, Gastroenterology, Oostende, Belgium;(7)University Hospital Leuven, Gastroenterology, Leuven, Belgium;
P577: A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1)*;Danese, S.(2);Colombel, J.F.(3);Rieder, F.(4);Yarur, A.(5);Verstockt, B.(6);Lichtiger, S.(7);Mosig, R.(8);Cataldi, F.(7);Feagan, B.(9);
(1)Nancy University Hospital- University of Lorraine, Department of Gastroenterology and Inserm NGERE U1256, Vandoeuvre-lès-Nancy, France;(2)IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Digestive Endoscopy, Milan, Italy;(3)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(4)Cleveland Clinic, Department of Inflammation and Immunity- Lerner Research Institute- Department of Gastroenterology- Hepatology and Nutrition- Digestive Disease Institute, Cleveland, United States;(5)Cedars Sinai Medical Center, Division of Gastroenterology and Hepatology- Center for Inflammatory Bowel Diseases, Los Angeles, United States;(6)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology- Department of Chronic Diseases and Metabolism, Leuven, Belgium;(7)Landos Biopharma- Inc, Clinical, Blacksburg, United States;(8)Landos Biopharma- Inc, Corporate Development, Blacksburg, United States;(9)Western University, Division of Gastroenterology- Department of Medicine, London, Canada;
P578: Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trialsECCO’23 CopenhagenYear: 2023
Authors: Panés, J.(1)*;Panaccione, R.(2);Sands, B.(3);Gasink, C.(4);Marano, C.(5);Ma, T.(4);Hoops, T.(6);
(1)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(2)University of Calgary, Inflammatory Bowel Disease Group, Calgary, Canada;(3)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(4)Janssen, Scientific Affairs, Horsham, United States;(5)Janssen, Research & Development, Spring House, United States;(6)Johnson & Johnson, Janssen Pharmaceutical Companies, Horsham, United States;
P579: Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS studyECCO’23 CopenhagenYear: 2023
Authors: Buisson, A.(1)*;Serrero, M.(2);Altwegg, R.(3);Guilmoteau, T.(1);Bouguen, G.(4);Nachury, M.(5);Amiot, A.(6);Vuitton, L.(7);Treton, X.(8);Caillo, L.(9);Pereira, B.(10);Fumery, M.(11);
(1)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;(2)AP-HM, IBD Unit, Marseille, France;(3)CHU Montpellier, IBD Unit, Montpellier, France;(4)CHU Rennes, IBD Unit, Rennes, France;(5)CHRU Lille, IBD Unit, Lille, France;(6)AP-HP, IBD-Unit, Le Kremlin-Bicêtre, France;(7)CHU Besançon, IBD Unit, Besançon, France;(8)AP-HP, IBD Unit, Paris, France;(9)CHU Nîmes, IBD Unit, Nîmes, France;(10)CHU Clermont-Ferrand, Biostatistics Unit, Clermont-Ferrand, France;(11)CHU Amiens, IBD Unit, Amiens, France;
P580: Upadacitinib is effective and safe for Ulcerative Colitis: prospective real-world experienceECCO’23 CopenhagenYear: 2023
Authors: Friedberg, S.(1)*;Choi, D.(1);Hunold, T.(1);Choi, N.K.(1);Garcia, N.M.(1);Picker, E.A.(1);Cohen, N.A.(1);Cohen, R.D.(1);Dalal, S.R.(1);Pekow, J.(1);Sakuraba, A.(1);Krugliak Cleveland, N.(1);Rubin, D.T.(1);
(1)University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States;
P581: Early biological therapy within the first 12 months after diagnosis leads to higher clinical, endoscopic, and transmural remission in Crohn's disease: European multicentre study with a propensity-score matched analysisECCO’23 CopenhagenYear: 2023
Authors: Revés, J.(1)*;Fernandez-Clotet, A.(2);Ordás, I.(2);Buisson, A.(3);Ellul, P.(4);Elorza, A.(5);Aduna, M.(6);Rodríguez-Lago, I.(5);Freire, G.(7);Sousa, P.(7);Primitivo, A.(7);Delgado, I.(7);Sousa Lajas, I.(8);Raimundo, A.(8);Bettencourt, P.(8,9);Rimola, J.(10);Torres, J.(1,11);
(1)Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal;(2)Hospital Clínic de Barcelona- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS- and CIBEREHD, Department of Gastroenterology, Barcelona, Spain;(3)Université Clermont Auvergne- Inserm- CHU Clermont-Ferrand, Department of Gastroenterology, Clermont-Ferrand, France;(4)Mater Dei Hospital, Division of Gastroenterology, Msida, Malta;(5)Hospital Universitario de Galdakao, Department of Gastroenterology, Galdakao, Spain;(6)OSATEK-hospital de Galdakao, Department of Radiology, Galdakao, Spain;(7)Hospital Beatriz Ângelo, Department of Radiology, Loures, Portugal;(8)Universidade Católica Portuguesa, Faculty of Medicine, Rio de Mouro, Portugal;(9)Universidade Católica Portuguesa, Centre for Interdisciplinary Research in Health, Lisbon, Portugal;(10)Hospital Clínic de Barcelona- IDIBAPS, Department of Radiology, Barcelona, Spain;(11)University of Lisbon, Faculty of Medicine, Lisbon, Portugal;
P582: Efficacy of etrasimod at week 52 among subjects who reached clinical response at week 12: post hoc analysis of the phase 3 ELEVATE UC 52 trialECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Sands, B.E.(2);Dubinsky, M.C.(3);Feagan, B.G.(4);Panaccione, R.(5);Jairath, V.(6);Yarur, A.(7);Chiorean, M.(8);Panés, J.(9);Goetsch, M.(10);Rabbat, C.J.(11);Shah, P.(12);Wu, J.(13);Ghosh, S.(14);
(1)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(2)Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Gastroenterology, New York- New York, United States;(3)Feinstein IBD Center- Mount Sinai, Gastroenterology, New York- New York, United States;(4)University of Western Ontario/Alimentiv Inc, Gastroenterology, London- Ontario, Canada;(5)Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology- University of Calgary, Gastroenterology and Hepatology, Calgary- Alberta, Canada;(6)Western University, Gastroenterology, London- Ontario, Canada;(7)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(8)IBD Center- Swedish Medical Center, Gastroenterology, Seattle- Washington, United States;(9)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(10)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(11)Pfizer Inc, Global Medical Affairs- Gastroenterology, New York- New York, United States;(12)Pfizer Inc, US Medical Affairs- Inflammation & Immunology, Collegeville- Pennsylvania, United States;(13)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(14)College of Medicine and Health- University College Cork, Gastroenterology, Cork, Ireland;
P584: Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitisECCO’23 CopenhagenYear: 2023
Authors: Jairath, V.(1)*;Bressler , B.(2);Silverberg , M.S.(3);Lee, L.Y.(4);Lugo, K.A.(4);Mayoral Monibas, R.(4);Annamalai, T.(4);Whitney, J.A.(4);Weng, E.Y.(4);Kanwar, B.(4);Danese , S.(5);Feagan, B.(1);
(1)Western University, Division of Gastroenterology, London- Ontario, Canada;(2)University of British Columbia, Division of Gastroenterology, Vancouver, Canada;(3)Mount Sinai Hospital- University of Toronto, Division of Gastroenterology, Toronto, Canada;(4)Applied Molecular Transport, Applied Molecular Transport, South San Francisco, United States;(5)University Vita-Salute San Raffaele, Division of Gastroenterology, Milan, Italy;
P585: Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North studyECCO’23 CopenhagenYear: 2023
Authors: Vermeire, S.(1)*;Abraham, B.(2);Bressler, B.(3);Reinisch, W.(4);Jain, A.(5);Memaj, A.(5);Akukwe, L.(5);Liu, W.J.(5);Osterman, M.(5);Canavan, J.B.(5);Sands, B.E.(6);
(1)University Hospitals Leuven, Chronic Diseases and Metabolism, Leuven, Belgium;(2)Houston Methodist Academic Institute, Gastroenterology, Houston, United States;(3)University of British Columbia, Medicine, Vancouver- BC, Canada;(4)Medical University of Vienna, Gastroenterology and Hepatology, Vienna, Austria;(5)Bristol Myers Squibb, Clinical Research, Princeton, United States;(6)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States;
P586: Vedolizumab in Mild to Moderate Crohn's Disease Patients Naïve to Biological Therapy: a Multicentric Observational StudyECCO’23 CopenhagenYear: 2023
Authors: Dotti, A.Z.(1);Vilela, E.G.(2);Chebli, J.M.F.(3);Chebli, L.A.(4);Magro, D.O.(5);Steinwurz, F.(6);Argollo, M.(7);Carvalho, N.S.(7);Parente, J.M.L.(8);Parra, R.S.(9);Perin, R.L.(10);Flores, C.(11);Morsoletto, E.M.(12);Ferreira, S.D.C.(13);Ludvig, J.C.(14);Kaiser Jr, R.L.(15);Queiroz, N.S.F.(16);Faria, M.A.G.(17);Nicollelli, G.M.(18);Andrade, A.R.(19);KotzeMD- PhD, P.G.(20)*;
(1)Universidade Federal do Paraná, Gastroenterology, Curitiba, Brazil;(2)Universidade Federal de Minas Gerais UFMG, Gastroenterology, Belo Horizonte, Brazil;(3)Universidade Federal de Juiz de Fora, Gastroewnterology, Juiz de Fora, Brazil;(4)Universidade Federal de Juiz de Fora, Gastroenterology, Juiz de Fora, Brazil;(5)University of Campinas UNICAMP, Colorectal Surgery, Campinas, Brazil;(6)Hospital Israelita Albert Einstein, Gastroenterology, Sao Paulo, Brazil;(7)Sao Luiz Hospital, Gastroenterology, Sao Paulo, Brazil;(8)Universidade Federal do Piaui, Gastroenterology, Teresina, Brazil;(9)Universidade de Sao Paulo, Colorectal Surgery, Ribeirao Preto, Brazil;(10)Universidade de Passo Fundo, Colorectal Surgery, Passo Fundo, Brazil;(11)Instituto do Aparelho Digestivo, Gastroenterology, Porto Alegre, Brazil;(12)Hospital Sao Vicente, Gastroenterology, Curitiba, Brazil;(13)Universidade de Sao Paulo, Gastroenterology, Ribeirao Preto, Brazil;(14)Clinica ESADI, Gastroenterology, Blumenau, Brazil;(15)Kaiser Clínica, Colorectal Surgery, Sao Jose do Rio Preto, Brazil;(16)Hospital Santa Cruz, Gastroenterology, Curitiba, Brazil;(17)Kaiser Clinica, Colorectal Surgery, Sao Jose do Rio Preto, Brazil;(18)Universidade Federal do Paraná, Colorectal Surgery, Curitiba, Brazil;(19)Universidade Estadual da Bahia, Gastroenterology, Salvador, Brazil;(20)Pontificia Universidade Católica do Paraná PUCPR, IBD outpatient Clinics, Curitiba, Brazil;
P587: Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) for monitoring of response to therapy in luminal Crohn's disease – a systematic review.ECCO’23 CopenhagenYear: 2023
Authors: Lovett, G.(1,2)*;Schulberg, J.D.(1,2);Hamilton, A.L.(1,2);Wilding, H.E.(3);Kamm, M.A.(1,2);Wright, E.K.(1,2);
(1)St Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine, Melbourne, Australia;(3)St Vincent's Hospital Melbourne, Library Service, Melbourne, Australia;
P588: Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Jairath, V.(1,2,3)*;Zou, G.(2,3,4);Wang, Z.(3);Adsul, S.(5);Colombel, J.F.(6);D'Haens, G.R.(7);Freire, M.(5);Moran, G.W.(8,9);Peyrin-Biroulet, L.(10);Sandborn, W.J.(11);Sebastian, S.(12,13);Travis, S.(14);Vermeire , S.(15);Radulescu, G.(3);Sigler, J.(3);Mcfarlane, S.(3);Arya, N.(16);Beaton, M.(1);Bossuyt, P.(17);Green, D.(18);Harlan III, W.(19);Horynski, M.(20);Klopocka, M.(21,22);Petroniene, R.(23);Silverberg, M.S.(24);Wolanski, L.(25);Feagan , B.G.(1,2,3);
(1)University of Western Ontario, Department of Medicine- Division of Gastroenterology, London, Canada;(2)University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada;(3)Alimentiv Inc., Medical Research and Development, London, Canada;(4)University of Western Ontario, Robarts Research Institute- Schulich School of Medicine and Dentistry, London, Canada;(5)Takeda Pharmaceuticals, Medical, Cambridge, United States;(6)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(7)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)University of Nottingham, Nottingham Digestive Diseases Biomedical Research Centre, Nottingham, United Kingdom;(9)Nottingham University Hospitals NHS Trust, NIHR Nottingham Biomedical Research Centre, Nottingham, United Kingdom;(10)Inserm NGERE U1256- University Hospital of Nancy- University of Lorraine, Department of Gastroenterology, Vandoeuvre-lès-Nancy, France;(11)University of California San Diego, Division of Gastroenterology, La Jolla, United States;(12)Hull Royal Infirmary, Hull and East Yorkshire NHS Trust & Hull and York Medical School, Hull, United Kingdom;(13)Hull York Medical School, School of Health & Life Sciences, Hull, United Kingdom;(14)University of Oxford, Kennedy Institute and Biomedical Research Centre, Oxford, United Kingdom;(15)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(16)ABP Research Services Corp., Gastroenterology, Oakville, Canada;(17)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(18)Taunton Surgical Centre, Department of Gastroenterology, Oshawa, Canada;(19)Asheville Gastroenterology Associates, Gastroenterology, Asheville, United States;(20)Endoskopia Sp. z.o.o., Gastroenterology, Sopot, Poland;(21)Collegium Medicum- Nicolaus Copernicus University, Department of Gastroenterology and Nutritional Disorders, Bydgoszcz, Poland;(22)Dr. Jana Biziel University Hospital n 2 in Bydgoszcz, Gastroenterology Clinic, Bydgoszcz, Poland;(23)Barrie GI Associates Inc., Gastroenterology, Barrie, Canada;(24)Toronto Immune and Digestive Health Institute, Gastroenterology, Toronto, Canada;(25)Independent Public Healthcare Center in Łęczna, Gastroenterological Department, Łęcznej, Poland;on behalf of the VERDICT Study Group
P589: Effectiveness of partial enteral nutrition to treat adults with Crohn's Disease who lost response to biological therapyECCO’23 CopenhagenYear: 2023
Authors: Nardone, O.M.(1)*;Calabrese, G.(2);Alfonsi, L.(3);Rispo, A.(2);La Mantia , A.(2);Fierro, G.(2);Ferrante, M.(2);Testa, A.(2);Guarino, A.D.(2);D'Alessandro, E.(2);Pasanisi, F.(3);Castiglione, F.(2);
(1)University Federico II of Naples, Gastroenterology- Department of Public Health, Naples, Italy;(2)University Federico II of Naples, Gastroenterology- Department of Clinical Medicine and Surgery, Naples, Italy;(3)University Federico II of Naples, Internal Medicine and Clinical Nutrition-Department of Clinical Medicine and Surgery, Naples, Italy;
P590: ADVANCED-UC TRIAL: AppenDectomy Vs ANti TNF-a in inducing Clinical and EnDoscopic remission in left-sided Ulcerative Colitis – A Randomized Clinical TrialECCO’23 CopenhagenYear: 2023
Authors: Luglio, G.(1)*;Rispo, A.(2);Tropeano, F.P.(3);Cricrì, M.(2);Castiglione, F.(2);De Palma, G.D.(2);
(1)University of Naples Federico II, Department of Public Health, Napoli, Italy;(2)University of Naples Federico II, Department of Clinical Medicine and Surgery, Naples, Italy;(3)University of Naples Federico II, Department of Advanced Biomedical Sciences, Naples, Italy;
